Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06524492 · ClinicalTrials.gov registry record
Flow Measurements in Functional CSF Shunts and Off-Shunt Locations with a Second-Generation Thermal Device
A clinical trial of Hydrocephalus, sponsored by Rhaeos.
- Completed
- Registry status
- 52
- Enrollment target
- 3
- Study locations
NCT06524492: Completed study of Hydrocephalus, sponsored by Rhaeos.
NCT06524492 is a study of Hydrocephalus that has completed, run by Rhaeos. The registered enrollment target is 52 participants, below the 130-participant average among 17 other Hydrocephalus trials with a reported enrollment target (60% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06524492, a study of Hydrocephalus, has completed, sponsored by Rhaeos.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of functional implanted shunts and off-shunt locations will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.
Primary Outcome
Study device sensitivity will be calculated as TP / (TP + FN).
Conditions Studied
Interventions
- DEVICE FlowSense
Study Locations (3)
Illinois
- Rhaeos, Inc. - Chicago
- Northwest Special Recreation Association - Rolling Meadows
Florida
- Tampa Marriott Water Street - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2024-07-27 |
What the finished NCT06524492 record still lists
NCT06524492 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 130-participant average among 17 other Hydrocephalus trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Hydrocephalus appearing as the primary indexed condition, and to 1 intervention - of which FlowSense is the first listed.
NCT06524492 reports a single indexed study location in Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT06524492 about?
NCT06524492 is a clinical study titled "Flow Measurements in Functional CSF Shunts and Off-Shunt Locations with a Second-Generation Thermal Device". This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of functional implanted shunts and off-shunt locations will assess the diagnostic non-inferiority of the second-generation device to the first-generation devic...
What is the current status of trial NCT06524492?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2024-07-25. Estimated completion is 2024-07-27.
What conditions does trial NCT06524492 study?
This clinical trial studies the following conditions: Hydrocephalus.
What interventions are being tested in trial NCT06524492?
The interventions under investigation include: FlowSense (DEVICE).
Who is sponsoring clinical trial NCT06524492?
This trial is sponsored by Rhaeos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06524492 being conducted?
This trial has 3 study locations across Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hydrocephalus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06524492's enrollment target sits among peer trials
52 12th of 17 higher than 6 of 17 other Hydrocephalus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hydrocephalus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NIRS Monitoring in Premature Infants
RECRUITING
-
Assessment of CSF Shunt Flow and Headaches With a Thermal Measurement Device
RECRUITING · NA
-
EVD Drainage Data and Intracranial Pressure (ICP) Measurements
RECRUITING · NA
-
Light Therapy Device for Neonatal Intraventricular Hemorrhage Grade 3 and 4
RECRUITING · NA
-
CoMind Early Feasibility Study
RECRUITING
-
Flow Detection in Open and Closed Shunt Valve Periods
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI